Physician profile
Stephanie A Mackey
NPI 1205834249
$103,654.54
in general payments reported to CMS, 2019-2025
28 companies · $3,117 in 2025
The $3,117 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $19K · 2021: $8,409 · 2022: $23K · 2023: $3,668 · 2024: $2,961 · 2025: $3,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,170 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,475 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,170.28 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,475.00 |
| Education | $101.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $66,809.12 | 2019-2025 | |
| Pfizer INC. | $29,266.37 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,354.64 | 2019-2025 | Absorica Ld, Winlevi, Ilumya |
| Novartis Pharmaceuticals Corporation | $904.71 | 2019-2025 | |
| Janssen Biotech, INC. | $807.73 | 2022-2025 | Tremfya |
| Galderma Laboratories, L.P. | $691.43 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Leo Pharma INC. | $611.43 | 2019-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $496.30 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Ucb, INC. | $483.91 | 2019-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $390.83 | 2023-2024 | Sotyktu |
| Genzyme Corporation | $371.92 | 2019-2025 | |
| Dermavant Sciences, INC. | $247.75 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $185.69 | 2021-2025 | Dupixent |
| Mayne Pharma Commercial LLC | $134.55 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $131.86 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $116.52 | 2024-2025 | Valchlor |
| Vyne Pharmaceuticals INC. | $95.77 | 2020-2021 | |
| Incyte Corporation | $81.41 | 2021-2024 | Opzelura |
| Dermira, INC. | $78.04 | 2019-2020 | |
| Encore Dermatology INC. | $77.29 | 2019 | |
| Epi Health, LLC | $61.99 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $60.84 | 2024-2025 | Zoryve |
| Genentech USA, INC. | $51.18 | 2020-2021 | |
| Nabriva Therapeutics, Plc | $41.36 | 2021 | |
| Organon LLC | $39.01 | 2025 | Vtama |
| Journey Medical Corporation | $32.42 | 2019-2020 | |
| Melinta Therapeutics, LLC | $15.82 | 2019 | |
| Mission Pharmacal Company | $14.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Mackey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.